Omeros (NASDAQ:OMER) Shares Gap Down – Here’s Why

Omeros Corporation (NASDAQ:OMER – Get Free Report) shares gapped down prior to trading on Tuesday. The stock had previously closed at $16.68, but opened at $14.59. Omeros shares last traded at $13.62, with a volume of 778,506 shares trading hands.

Key Headlines Impacting Omeros

These are some of the OMER headlines that stood out recently:

  • Positive Sentiment: HC Wainwright raised its FY2027 earnings-per-share estimate to $0.33 from $0.24, reaffirmed its Buy rating, and kept a $33 price target. HC Wainwright estimate update
  • Neutral Sentiment: YARTEMLEA sales increased sequentially, showing commercial progress, though analysts also noted a deceleration in the quarter. Q3 2026 earnings call summary
  • Negative Sentiment: Q3 results disappointed on revenue and included a wider loss, while a setback for YARTEMLEA in Europe added uncertainty about the drug’s growth prospects. These concerns drove a sharp decline in the shares after the results. YARTEMLEA setback and share reaction Q3 results and stock reaction

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $22.00 target price on shares of Omeros in a research report on Wednesday, October 14th. HC Wainwright restated a “buy” rating and set a $33.00 price objective on shares of Omeros in a research report on Tuesday. Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and an average target price of $30.33.

View Our Latest Stock Report on Omeros

Omeros Price Performance

The firm has a market cap of $1.05 billion, a P/E ratio of 15.16 and a beta of 2.96. The company has a fifty day moving average of $18.02 and a 200-day moving average of $13.79.

Omeros (NASDAQ:OMER – Get Free Report) last announced its earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. The business had revenue of $35.93 million during the quarter, compared to analysts’ expectations of $37.28 million. On average, sell-side analysts expect that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling at Omeros

In related news, VP Peter B. Cancelmo sold 25,000 shares of the business’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the sale, the vice president directly owned 200 shares in the company, valued at approximately $3,708. The trade was a 99.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO David J. Borges sold 10,000 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $20.95, for a total transaction of $209,500.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares in the company, valued at approximately $104,750. The trade was a 66.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 85,906 shares of company stock valued at $1,628,205 over the last three months. 10.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OMER. Sterling Capital Management LLC raised its stake in shares of Omeros by 75.3% during the third quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 758 shares during the last quarter. GK Wealth Management LLC bought a new position in Omeros during the 3rd quarter valued at approximately $65,000. Assetmark Inc. purchased a new position in shares of Omeros in the 1st quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Omeros in the third quarter worth about $70,000. Finally, Parallel Advisors LLC lifted its position in Omeros by 778.1% in the 3rd quarter. Parallel Advisors LLC now owns 6,586 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 5,836 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

See Also

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.